Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions

被引：34

作者：

Colella, G

Pennati, M

Bearzatto, A

Leone, R

Colangelo, D

Manzotti, C

Daidone, MG

Zaffaroni, N

机构：

[1] Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy

[2] Univ Verona, Dept Pharmacol, I-37134 Verona, Italy

[3] Univ Turin, Dept Med Sci, I-28100 Novara, Italy

[4] Novuspharma SpA, I-20052 Monza, Italy

来源：

BRITISH JOURNAL OF CANCER | 2001年 / 84卷 / 10期

关键词：

BBR; 3464; cisplatin; DNA repair; ovarian cancer;

D O I：

10.1054/bjoc.2001.1751

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A collateral sensitivity or a very modest cross-resistance to BBR 3464 was found in 2 ovarian cancer cell lines with experimentally induced resistance to cisplatin. Loss of mismatch repair proteins (hMLH1, hPMS2) or overexpression of nucleotide excision repair proteins (ERCC1) was not detrimental for the cellular sensitivity to BBR 3464. Moreover, interesting differences in the kinetics of formation and removal of DNA lesions at the single-gene (N-ras) level were observed between BBR 3464 and CDDP. (C) 2001 Cancer Research Campaign.

引用

页码：1387 / 1390

页数：4

共 11 条

[1]

BEHRENS BC, 1987, CANCER RES, V47, P414

[2] DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent [J].